Guidelines for management of Cytokine Release Syndrome

Organisation: The Christie NHS Foundation Trust

Document version number: 8

Date written: 10.5.21

End user rights:

This document is shared with permission for re-use to distribute, remix, adapt, and build upon the material in any medium or format for non-commercial purposes only, so long as the attributions listed below are given.

Attributions: The Christie NHS Foundation Trust

This document is made available under a Creative Commons Attribution-NonCommercial 4.0 International License as described here:

https://creativecommons.org/licenses/by-nc/4.0/

The information, materials and any opinions contained in this document are provided for general information and educational purposes only, are not intended to constitute legal, medical or other professional advice and should not be relied on or treated as a substitute for specific advice relevant to particular circumstances. Although we make all reasonable efforts to ensure the information is up to date, we make no representations, warranties or guarantees in that regard. In no event shall the creator(s) be liable for any direct, indirect, special, consequential or other claims, losses or damages that are related to the use or reliance whatsoever in the content of the document or any part thereof, except to the extent that such liability cannot be excluded by law. We do not seek to exclude or limit in any way our liability to the user for personal injury or death caused as a result of our negligence or seek to exclude or limit our liability for fraud or fraudulent misrepresentation by us.
We reserve the right to make changes and improvements to any information contained within this document, at any time and without notice. Where this document contains hyperlinks to other websites operated by parties not connected to us, such hyperlinks are provided for your reference only. We do not control such websites and are not responsible for their contents. The inclusion of hyperlinks from this document or the website to such websites does not imply any endorsement of the material on such websites or any association with their operators. We accept no responsibility of any nature whatsoever for linked web sites or any information contained in them.
1.0 INDICATIONS OF PRACTICE

Cytokine release syndrome (CRS) is a serious and potentially life threatening complication associated with cancer immunotherapies. This is the most common serious toxicity of cellular immunotherapy triggered by activation of T-cells on engagement with target antigen leading to release of inflammatory cytokines and chemokines (including IL-2, soluble IL-2α receptor, IL-6, INF-γ, GM-CSF) and activation of immune effector cells (including macrophages, monocytes and dendritic cells). For patients treated with CAR-T therapy, IL-6 plays a pivotal role in the development of CRS. Treatments which have been associated with development of CRS are as listed below and this document focuses on management of CRS with cellular therapies (notably CAR-T cells) and bi-specific T cell engaging antibodies (eg blinatumomab).

<table>
<thead>
<tr>
<th>Immune checkpoint inhibitors</th>
<th>Anti-CTLA4 – ipilimumab Anti-PD(L)1 – nivolumab,pembrolizumab, avelumab</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD3/CD19 bispecific antibodies</td>
<td>Blinatumumab</td>
</tr>
<tr>
<td>Genetically unmodified cytotoxic T cells (CTL) therapy</td>
<td>Tumour-Infiltrating lymphocytes (TIL) EBV-specific CTL</td>
</tr>
<tr>
<td>Chimeric Antigen Receptor Therapy (CAR-T)</td>
<td>Most common with anti-CD19</td>
</tr>
<tr>
<td>Others</td>
<td>High dose IL-2, alemtuzumab, donor lymphocyte infusion, Haplo-identical transplant</td>
</tr>
</tbody>
</table>
For patients participating in clinical trials the management of cytokine release syndrome may be defined within the trial protocol. It is a regulatory requirement that clinical trials are approved by the national competent authority, MHRA and a research ethics committee. In addition clinical trial protocols must undergo a local capacity and capability review to ensure the research can be conducted in accordance with the protocol (Approving apheresis and high risk immune effector cell trials SOP (QM-11) and R&D001.000 Study Set Up - Capacity and Capability Process). This SOP and trial protocol should be used in conjunction where a patient is participating in a clinical trial.

2.0 AUTHORISED PERSONNEL/TRAINING REQUIRED

Medical staff: should be familiar with the diagnosis of CRS post cellular therapies and their management. Additionally, education should extend to the identification of risk factors and preventive measures.

Nursing staff: the nursing team should be aware of the needs of patient with CRS following cellular therapies as well as the pathology and risk factors for its development. Student nurses and HCA should be supervised and seek guidance when attending to patients with neurological disease.

3.0 CLINICAL PRESENTATION

3.1 Incidence and timing – CAR-T therapy

The reported incidence of CRS is variable and depends on the CAR construct and the therapeutic target. The highest incidence of CRS has been reported with anti-CD19 CAR-T where more than 50% of patients may be expected to develop evidence of CRS with 15-25% of patients developing ≥3 toxicity. Serious CRS is observed more frequently in

- Increased tumour bulk
- Elderly patients
- Patients with impaired organ function or co-morbidity
- Early onset CRS (within 3 days of infusion)

CRS is dependent on the engagement of T-cells with target antigen. The onset is dependent on the kinetics of T-cell activation and as such this varies with the CAR-T construct used (due to different T-cell co-stimulatory domains used). This is however usually observed within 14 days of treatment and is rarely observed more than 17 days after treatment.

3.2 Incidence and timing - blinatumomab

CRS following administration of blinatumomab is generally only observed during the first cycle of treatment and likelihood is a factor of disease burden and dose of treatment employed. The protocol employed utilises steroid pre-medication and treated
is started at a reduced dose level; in addition cytoreduction with steroids or cytotoxics is recommended before blinatumomab therapy. Using this protocol treatment related fever is common (observed in >50% of patients) although grade 3-4 CRS is only observed in 2% of patients.

3.3 Symptoms

A wide variety of symptoms have been reported. Early symptoms include fever (may be >40°C), malaise, myalgia and anorexia. Progressive disease can affect any organ system.

Characteristic symptoms include

- Progressive fever
- Tachycardia
- Capillary leak syndrome leading to hypoxia and pulmonary infiltrates
- Hepato-renal dysfunction
- Hypofibrinogenenaemia
- Hypotension which is the hallmark of disease severity

Do not remove from SOP folder. Do not photocopy
4.0 MONITORING

For guidance on inpatient assessment see SOP: Inpatient Management of patients receiving Immune Effector Cells (including Car-T Cells)

4.1 Observations

General observations (vital signs, NEWS2 score, VIP score, weight, skin assessment, mouth assessment, fluid balance, bowel assessment) will be performed according to the SOP: Nursing Observations for all Haematology and Stem Cell Transplant Patients and Trust News2 policy (SOP: National Early Warning Score 2 (NEWS2) policy

- Vital signs will be recorded every 4 hours for all patients
- More frequent observations will be performed according to patient’s clinical condition

4.2 Laboratory tests

Patients require daily blood tests with additional monitoring (CAR-T patients) for treatment related complications (eg infection – CRP, coagulopathy – coag and fibrinogen, HLH – ferritin); see SOP: Palatine Ward routine samples). Additional blood testing is not generally recommended for patients treated with blinatumomab due to the significantly lower risk of serious CRS although may be indicated for selected high risk patients (eg those with high disease burden); this should be discussed with (Attending) Consultant. High risk testing schedule is as below:

- Daily FBC, Christie profile, coagulation (Clauss fibrinogen), CRP, ferritin, magnesium
- Glucose three times per week

Patients developing CRS will typically show laboratory evidence of acute inflammation (raised CRP and ferritin) and may develop hypofibrinogenaemia (see SOP: Inpatient Management of patients receiving Immune Effector Cells (including CAR-T Cells). These are not however present in all patients and laboratory parameters cannot be relied on in isolation to make a diagnosis. Inflammatory cytokine panels may be predictive of the onset and severity of CRS although are currently their use is restricted to clinical trials and they are not recommended for routine use.
### 4.3 Other investigations

Other investigations (ECG, echocardiogram, arterial blood gas monitoring, lactate, multi-site cultures, CXR or other imaging) should be requested according to clinical requirements.

### 4.4 CRS monitoring

All CAR-T patients and selected other high risk patients (eg high tumour burden patients treated with blinatumomab) will be monitored at least twice daily for evidence of CRS. More frequent monitoring is indicated for patients with evidence of clinical deterioration or as directed by Attending Consultant. For details and patient monitoring chart see SOP: Inpatient Management of patients receiving Immune Effector Cells (including Car-T Cells)

### 5.0 STAGING

A number of staging systems have been described for CRS including adapted CTCAE and scales developed at MD Anderson Cancer Centre (MDACC) and University of Pennsylvania (Penn), and ASTCT (American society for Transplantation and Cellular Therapy, formally ASBMT) which are tabulated below. Although some trial protocols stipulate the use of a particular grading system, the **ASTCT consensus grading system** is recommended for routine use in order to harmonise toxicity grading for all patients. Patients will be assessed and monitored at least twice per day and CRS graded according to the ASTCT staging system (see SOP: Inpatient Management of patients receiving Immune Effector Cells (including Car-T Cells).

<table>
<thead>
<tr>
<th>Grade</th>
<th>ASTCT</th>
<th>MDACC</th>
<th>CTCAE</th>
<th>Penn</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Temperature &gt;38.0</td>
<td>Symptoms are not life-threatening and require symptomatic treatment only, e.g., fever, nausea, fatigue, headache, myalgias, malaise</td>
<td>Mild reaction; infusion interruption not indicated; intervention not indicated</td>
<td>Mild reaction: treated with supportive care such as antipyretics, antiemetics</td>
</tr>
<tr>
<td>2</td>
<td>Fever &gt; 38.0 With Hypotension -not requiring Vasopressor And/or hypoxia requiring low flow nasal cannula (&lt;6l/minute)</td>
<td>Symptoms require and respond to moderate intervention. Oxygen requirement &lt; 40% or hypotension responsive to fluids or low-dose pressors or grade 2 organ toxicity</td>
<td>Therapy or infusion interruption indicated but responds promptly to symptomatic treatment (e.g., antihistamines, NSAIDs, narcotics, IV fluids); prophylactic medications indicated for ≤ 24 h</td>
<td>Moderate reaction: some signs of organ dysfunction (e.g., grade 2 creatinine or grade 3 LFTs) related to CRS and not attributable to any other condition. Hospitalization for management of CRS-related symptoms, including fevers with associated neutropenia, need for IV therapies (not including fluid resuscitation for hypotension)</td>
</tr>
</tbody>
</table>
### POLICY

**TITLE: GUIDELINES FOR MANAGEMENT OF CYTOKINE RELEASE SYNDROME**

<table>
<thead>
<tr>
<th>Grade</th>
<th>Description</th>
<th>Symptoms</th>
<th>Prolonged Reaction</th>
<th>More Severe Reaction</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td>Hypotension Requiring vasopressors with or without vasopressors And/or Requiring high flow nasal cannula (&gt; 6l/minute), facemask, non rebreather mask or venturi mask</td>
<td>Symptoms require and respond to aggressive intervention. Oxygen requirement ≥ 40% or hypotension requiring high-dose or multiple pressors or grade 3 organ toxicity or grade 4 transaminitis</td>
<td>Prolonged reaction (e.g., not rapidly responsive to symptomatic medication and/or brief interruption of infusion); recurrence of symptoms following initial improvement; hospitalization indicated for clinical sequelae (e.g., renal impairment, pulmonary infiltrates)</td>
<td>More severe reaction: hospitalization required for management of symptoms related to organ dysfunction, including grade 4 LFTs or grade 3 creatinine related to CRS and not attributable to any other conditions; this excludes management of fever or myalgias; includes hypotension treated with intravenous fluids (defined as multiple fluid boluses for blood pressure support) or low-dose vasopressors, coagulopathy requiring fresh frozen plasma or cryoprecipitate or fibrinogen concentrate, and hypoxia requiring supplemental oxygen (nasal cannula oxygen, high-flow oxygen, CPAP, or BIPAP). Patients admitted for management of suspected infection due to fevers and/or neutropenia may have grade 2 CRS</td>
</tr>
<tr>
<td>4</td>
<td>Requiring positive pressure (e.g., CPAP &lt; BIPPAP), intubation and mechanical ventilation</td>
<td>Life-threatening symptoms. Requirements for ventilator support or grade 4 oxygen toxicity (excluding transaminitis)</td>
<td>Life-threatening consequences; pressor or ventilator support indicated</td>
<td>Life-threatening complications such as hypotension requiring high-dose vasopressors, a hypoxia requiring mechanical ventilation</td>
</tr>
</tbody>
</table>

- CRS grade is determined by the more severe event; hypotension or hypoxia not attributable to any other cause. For example a patient with a temp of 39.5, hypotension, and hypoxia requiring low-flow oxygen is classified as grade 2 CRS.
- Onset of CRS is defined by fevers with or without constitutional symptoms which are no a result of other causes (e.g. infection)
- Unstable hypotension is the hallmark of severe CRS
- Grading of high dose vs low dose inotropes is as below (not required for ASTCT grading)
**POLICY**

**TITLE: GUIDELINES FOR MANAGEMENT OF CYTOKINE RELEASE SYNDROME**

<table>
<thead>
<tr>
<th>Vasopressor</th>
<th>High dose definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Noradrenaline monotherapy</td>
<td>Greater than or equal to 20 mcg/minute</td>
</tr>
<tr>
<td>Dopamine monotherapy</td>
<td>Greater than or equal to 10 mcg/kg/minute</td>
</tr>
<tr>
<td>Phenylephrine monotherapy</td>
<td>Greater than or equal to 200 mcg/minute</td>
</tr>
<tr>
<td>Adrenaline monotherapy</td>
<td>Greater than or equal to 10 mcg/minute</td>
</tr>
<tr>
<td>Vasopressin</td>
<td>Vasopressin + noradrenaline equivalent of greater than or equal to 10 mcg/minute</td>
</tr>
<tr>
<td>Combination therapy (not including vasopressin)</td>
<td>Noradrenaline equivalent of greater than or equal to 20 mcg/minute</td>
</tr>
</tbody>
</table>

**6.0 TREATMENT**

6.1 Treatment principles

Principles of treatment are as follows:

- Risk assess patient prior to treatment (age, comorbidity, disease bulk, treatment used)
- Monitor closely during high risk period (for the first 14 days post infusion)
- Increased monitoring and escalation in the event of any deterioration. All patients need supportive care and some may require intensive supportive therapy but most organ dysfunction is reversible
- Consider alternative/co-existent pathologies (e.g., sepsis)
- Risk of CRS following blinatumomab is reduced by pre-treatment cytoreduction and steroids. Specific intervention (IL-6 antagonists +/- steroids) for patients with grade 2 or progressive disease.
- Observe closely for evidence of additional neurotoxicity which may co-exist and requires earlier intervention with steroids.
- Early intervention should be considered in high risk patients or those with early onset disease (e.g., within 3 days of CAR-T therapy)
- Unstable hypotension is the hallmark of severe CRS
6.2 Supportive therapy

All patients should receive supportive therapy

- Paracetamol for treatment of fever
- Analgesia if required
- Treat sepsis as per policy and investigate for source of infection (cultures, imaging as required)
- Intravenous fluids (maintenance hydration and normal saline boluses as required for management of hypotension)
- Supplementary oxygen if indicated to maintain SpO2 >90%
- Careful fluid balance
- Escalation (outreach, critical care) as per NEWS2 policy
- Monitoring as per CAR-T monitoring protocol (twice daily assessment or more frequently if deterioration, changes in condition or as directed by Consultant staff)
- Assess for neurotoxicity and treat accordingly.
6.3 Additional treatment – CAR-T therapy

Additional treatment is as indicated by grade of toxicity. Additional guidance should also be used as indicated for patients in clinical trials in accordance with trial protocol.

<table>
<thead>
<tr>
<th>ASTCT Grade</th>
<th>Symptom or sign</th>
<th>Management</th>
</tr>
</thead>
</table>
| 1           | Fever or organ toxicity\(^1\) | • Vigilant supportive care  
• Monitor vital signs 4 hourly  
• Investigate for and treat potential infection  
• Administer IV fluids (keep well hydrated), antibiotics, paracetamol as clinically indicated  
• If persistent for 3 days administer Tocilizumab 8mg/kg IV (max 800mg) |
| 2           | Hypotension\(^1\) | • Administer IV fluid bolus (10-30 mg/kg capped at 500-1000ml over 30-60 min). Fluid overload should be avoided.  
• Administer Tocilizumab 8mg/kg IV (max 800mg)  
• Inform CCU Consultant and outreach team  
• Assess BP response to fluid bolus. If patient fails to respond to IV fluid bolus (SBP<90mmHg) and if no response to 2 doses of tocilizumab or deteriorating condition then for administer dexamethasone\(^2\) 10mg IV  
• If tocilizumab not available or persistent CRS after 4 doses, commence Anakinra 1-2 mg/kg SC (or IV) infusion (100 mg dose or 1 vial), increasing to a maximum dose of 10 mg/kg as required  
• If tocilizumab not available administer siltuxumab 11mg/kg single dose – cannot repeat in < 3 weeks  
• If siltuximab not available, administer Anakinra 1-2 mg/kg SC (or IV) infusion (100 mg dose or 1 vial), increasing to a maximum dose of 10 mg/kg as required  
• Discuss with attending or on-call Haematology consultant |
|             | Hypoxia\(^1\) | • As above for hypotension grade 2  
• Administer Oxygen  
• Manage fluid overload if present.  
• Investigate for and treat potential infection  
• Inform CCU Consultant and outreach team  
• If higher doses are required consider |
### TITLE: GUIDELINES FOR MANAGEMENT OF CYTOKINE RELEASE SYNDROME

<table>
<thead>
<tr>
<th>Hypotension</th>
<th>3</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Humidified oxygen. If required escalate to a non-rebreather</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Inform CCU Consultant and outreach team</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Admit to critical care.</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Commence vasopressor therapy</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Administer supportive treatment as in Grade 2 CRS</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Administer Tocilizumab as per grade 2 CRS if not administered previously</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Increase Anakinra dose up to 10 mg/kg SC (or IV) infusion (in 100 mg or 1 vial intervals)</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Administer regular Dexamethasone 9.9mg (3ml) IV 6 hourly, increase to 19.8mg (6ml) IV 6 hourly if refractory</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Continuous ECG monitoring &amp; urgent echocardiogram, if feasible</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Discuss with attending or on-call Haematology consultant</strong></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Hypoxia</th>
<th>4</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Inform CCU Consultant and outreach team</strong></td>
<td></td>
</tr>
<tr>
<td><strong>As above for hypotension grade 3</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Administer high flow oxygen as in Grade 2 CRS</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Manage fluid overload if present.</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Investigate for and treat potential infection</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Nasal/face mask high flow oxygen or non-invasive ventilation (should be avoided during COVID-19 pandemic to limit viral spread, if possible)</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Consider intubation for invasive mechanical ventilation as per grade 4</strong></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Hypotension</th>
<th>4</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Inform CCU Consultant and outreach team</strong></td>
<td></td>
</tr>
<tr>
<td><strong>As above for hypotension grade 3</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Admit to critical care</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Discuss with attending or on-call Haematology consultant</strong></td>
<td></td>
</tr>
<tr>
<td><strong>As per grade 3 and administer methylprednisolone IV 2 mg/kg/day in divided doses for up to 7 days.</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Administer a higher dose of methylprednisolone IV (500-1000 mg/day) if no response</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Consider anti T-cell therapy (eg cyclophosphamide 1.5g/m²) if no response after discussion with cellular/CAR-T therapies consultant and attending Haematology consultant</strong></td>
<td></td>
</tr>
</tbody>
</table>
Hypoxia

- As above for hypotension grade 4
- Administer high flow oxygen as in Grade 3 CRS
- Manage fluid overload if present.
- Investigate for and treat potential infection
- Nasal/face mask high flow oxygen or non-invasive ventilation (should be avoided during COVID-19 pandemic to limit viral spread, if possible)
- Consider intubation for invasive mechanical ventilation

6.4 Additional treatment – blinatumomab

CRS following blinatumomab can generally be managed with pausing the infusion and additional doses of steroids (dexamethasone 10-20mg iv). Treatment may be re-started at reduced dose once CRS resolves for grade 3 toxicity but should be permanently discontinued for patients with grade 4 CRS as per drug SPC. In the event of patients not responding to steroids, then patients should be treated with tocilizumab as per CAR-T therapy.

7.0 USE OF IL-6 ANTAGONISTS

IL-6 antagonists are the mainstay of treatment for CRS complicating CAR-T therapy requiring management beyond supportive care. Although CRS is associated with increased levels of a range of inflammatory cytokines, IL-6 is central to CRS pathogenesis.

7.1 Tocilizumab

IL-6 receptor antagonist used as first line therapy.

- 8mg/kg by iv bolus (maximum 800mg)
- Doses can be repeated every 6-8 hours (up to 3 doses in 24 hours) up to maximum of 4 doses

1Early intervention with IL-6 antagonists and steroids should be considered in high risk patients (CRS onset within 3 days of treatment, bulky disease, patients > 60 years or patients with co-morbidity or organ dysfunction

2Steroids are effective for treatment of CRS. Dexamethasone is first line therapy and where started should be continued for at least 3 days or until CRS resolution. Routine use (eg as pre-medication for transfusions or treatment of uncomplicated fever) should be avoided as steroids may impact on the efficacy of CAR-T treatment. In general steroids are therefore reserved for patients who don’t respond to IL-6 antagonists

Patients with organ dysfunction (CTCAE grade 3 or above) attributable to CRS without other cause may also be considered for treatment with tocilizumab if this has not already been started. To be discussed with attending or on call consultant.
7.2 Anakinra (Kineret)

Human interleukin-1 receptor antagonist to be used as second line therapy at The Christie. This product is licenced for use in rheumatoid arthritis and other inflammatory syndromes but not currently licensed for cytokine release syndrome although has been used to successfully treat CRS.

To be considered as second line therapy for patients not responding to at least 2 previous doses of tocilizumab.

Anakinra will be stocked in critical care and must be agreed by the attending critical care and haematology consultants.

The dose of anakinra in CRS is 200mg once daily by subcutaneous injection continued until 24 hours after resolution of CRS. See SPC for more information https://www.medicines.org.uk/emc/product/559/smpc#

Available in 100 mg/0.67 ml solution for injection in pre-filled syringe.

8.0 REFERENCES

- SOP: Inpatient Management of patients receiving Immune Effector Cells (including Car-T Cells)
- SOP: Guidelines for the management of sepsis,
- SOP: National Early Warning Score 2 (NEWS2) policy
- SOP: Tumour lysis
- SOP: Neurological disease in Stem Cell Transplantation and Cellular Therapy
- Brudno JN & Kochenderfer JN Blood 2016;127:3321
- Teachey DT et al. Cancer Discov 2016;6:664